Summary
The development of T cells from stem (progenitor) cells to effector cells results from a two-wave process of proliferation and differentiation. The cells of the first differentiation wave are the precursor T cells, and those of the second differentiation wave are peripheral T cells. In the first differentiation wave, resting/circulating naive antigen-reactive T lymphocytes are produced which differ from each other in their antigen receptor-specificity. In the second differentiation wave, those T lymphocytes multiply whose antigen receptors have found the corresponding antigen. Thus three major forms of differentiation can be distinguished in the peripheral T cells: (1) resting/circulating naive antigen-reactive T cells, (2) activated T cells, and (3) effector T cells and memory T cells. In addition, there are at least three major organ-restricted sublines of peripheral T cells, i.e., nodal T cells, mucosa-associated T cells, and skin-associated T cells. Thanks to the availability of markers for most of the above-mentioned T-cell sublines and differentiation forms, all these cellular forms can be associated with certain lymphoma types, i.e., lymphomas of T-cell type can be divided into categories of precursor T-cell lymphomas and peripheral T-cell lymphomas. The peripheral T-cell lymphomas can be subdivided into those derived from lymph nodal, mucosal, and cutaneous T cells. The gut mucosal T-cell lymphomas are associated with enteropathy. The lymph node, mucosal, and cutaneous T-cell lymphomas can be further subdivided into those in which all tumor cells are similar to recirculating resting (nonactivated) T cells, those in which some of the tumor cells resemble activated T cells, and those in which all tumor cells resemble activated T cells. The second group includes pleomorphic T-cell lymphoma, Lennert’s lymphoma, and angioimmunoblastic T-cell lymphoma, and the third group includes Ki-1+ (CD30+) anaplastic large-cell (ALC) lymphomas of T-cell type. The apparently constant association of Ki-1+ T-ALC lymphoma with the breakpoint 5q35 underlines the justification of its classification as a separate entity.
Keywords
Celiac Disease Antigen Receptor Anaplastic Large Cell Lymphoma Hairy Cell Leukemia Differentiation WavePreview
Unable to display preview. Download preview PDF.
References
- 1.Janossy G, Grant-Prentice H. T-cell subpopulations, monoclonal antibodies and their therapeutic applications. Clin Haematol 1982; 11: 631–660.PubMedGoogle Scholar
- 2.Foon KA. Todd RF 3d. Immunologic classification of leukemia and lymphoma. Blood 1986; 68: 1–31.PubMedGoogle Scholar
- 3.Stein H, Mason DY, Gerdes J, O’Conner N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K. The expression of the Hodgkin’s disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue.–Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858.PubMedGoogle Scholar
- 4.Stein H, Gerdes J. Phänotypische and genotypische Marker bei malignen Lymphomen. Ein Beitrag zum zellulären Ursprung des Morbus Hodgkin and der malignen Histiozytose sowie Implikationen für die Klassifikation der T-Zell and B-ZellLymphome. Verh. Dtsch. Ges. Path. 1986; 70: 127–151.Google Scholar
- 5.Stein H, Dallenbach F, Dienemann D. Differenzierungslinien physiologischer and maligner Zellen des lymphatischen Systems. Verh Dtsch Ges Pathol 1988; 72: 57–85.PubMedGoogle Scholar
- 6.Suchi T, Lennert K, Tu LY, Kikuchi M, Sato E, Stansfeld AG, Feller AC. Histopathology and immunohistochemistry of peripheral T-cell lymphomas: a proposal for their classification. J Clin Pathol 1987; 40: 995.PubMedCrossRefGoogle Scholar
- 7.Stansfeld AG, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundström C, van Unnik JAM, Wright DH. Updated Kiel Classification for lymphomas. Lancet 1988; is 292–293.Google Scholar
- 8.Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin’s lymphoma. Am J Pathol 1987; 128: 181–201.PubMedGoogle Scholar
- 9.Said JW, Shintaku IP, Parekh K, Pinkus GS. Specific phenotyping of T cell proliferations in formol-fixed paraffin-embedded tissues: Use of antibodies to the T cell receptor ßF1. Am J Clin Pathol 1990; 93: 382–386.PubMedGoogle Scholar
- 10.Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, Rigal-Huguet F, Robert A, Stein H, Mason DY. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Am J Pathol 1988; 130: 59–70.PubMedGoogle Scholar
- 11.Isaacson PG, Spencer J, Connolly CE, Pollock DJ, Stein H, O’Conner NTJ, Bevan DH, Kirkham N, Wainscoat JS, MaSON DY. Malignant histiocytosis of the intestine: A T cell lymphoma. Lancet 1985; ii: 688–691.Google Scholar
- 12.Weiss LM, Trela MJ, Cleary ML, Turner RR, Warnke RA, Sklar E. Frequent immunoglobulin and T cell receptor gene rearrangements in `histiocytic’ neoplasms. Am J Pathol 1985; 121: 369–373.PubMedGoogle Scholar
- 13.Beljaards RC, Meijer CJLM, Scheffer E, Toonstra J, van vloten WA, van der Putte SCJ, Geerts ML, Willemze R. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large cell lymphomas of T origin: a clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989; 135: 1169–1178.PubMedGoogle Scholar
- 14.Engelhard M, von Schilling C, Diehl V, Pfreundschuh M, Brittinger G, Feller AC, Stein H, Zwingers T, Lennert K. Clinical analysis of Ki-1 lymphoma. Blut 1986; 53: 220 (abstract).Google Scholar
- 15.Engelhard M, von Schilling C, Diehl V, Pfreundschuh M, Brittinger G, Zwingers T, Feller AC, Stein H, Lennert K. CD30 (Ki-1)’ lymphoma: morphological and immunohistological characterization, identification of three subentities, and clinical analysis of 92 cases. Blood 1990; (submitted).Google Scholar
- 16.Kaudewitz P, Stein H, Dallenbach F, Eckert F, Bieber K, Burg G, Braun-Falco O. Primary and secondary Cuntaneous Ki-1 (CD30’) Anaplastic Large Cell Lymphomas. Morphologic, Immunohistologic, and Clinical Characteristics. Am J Pathol 1989; 135: 359–367.PubMedGoogle Scholar
- 17.Morgan R, Hecht BK, Sandberg AA, Hecht F, Smith SD. Chromosome 5q35 breakpoint in malignant histiocytosis. N Eng J Med 1986; 314: 1322 (Letter).Google Scholar
- 18.Mason DY, Bastard C, Rimokh R, Dastugue N, Huret JL, Kristoffersson U, Magaud JP, Nezelof C, Tilly H, Vanier JP, Hemet J, Warnke R. CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35. Brit J Haematol 1990; 74: 161–168.CrossRefGoogle Scholar
- 19.Bitter MA, Franklin WA, Larson RA, McKeithan TW, Rubin CM, Le Beau MM, Stephens JK, Vardiman JW. Morphology in Ki-1 (CD30)-positive non-Hodgkin’s lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2; 5) (p23; q35). Am J Surg Pathol 1990; 14: 305–316.PubMedCrossRefGoogle Scholar
- 20.Fairley NH, Mackiew FP. Clinical and biochemical syndrome in lymphadenoma and allied diseases involving mesenteric lymph glands. Brit Med J 1937; 1: 375–380.PubMedCrossRefGoogle Scholar
- 21.Isaacson PG, Wright DH. Malignant histiocytosis of the intestine: its relationship to malabsorption and ulcerative jejunitis. Hum Pathol 1978; 9: 661–677.PubMedCrossRefGoogle Scholar
- 22.Guy-Grand D, Griscelli C, Vassali P. The mouse gut T lymphocyte, a noval type of T cell: Nature, origin, and traffic in mice in normal graft-versus-host conditions. J Exp Med 1978; 148: 1661–1677.PubMedCrossRefGoogle Scholar
- 23.Cerf-Bensussan N, Jarry A, Brousse N, Lisowska-Grospierre B, Guy-Grand D, Griscelli C. A monoclonal antibody (HML1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur J Immunol 1987; 17: 1279–1285.PubMedCrossRefGoogle Scholar
- 24.Spencer J, Cerf-Bensussan N, Jarry A, Brousse N, Guy-Grand D, Krajewski AS, Isaacson PG. Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am J Pathol 1988; 132: 1–5.PubMedCrossRefGoogle Scholar
- 25.Stein H, Dienemann D, Sperling M, Zeitz M, Riecken EO. Identification of a T cell lymphoma category derived from intestinal mucosa-associated T cells. Lancet 1988; ii: 10531954.Google Scholar
- 26.Visser L, Shaw A, Slupsky J, Vos H, Poppema S. Monoclonal antibodies reactive with hairy cell leukemia. Blood 1989; 74: 320–325.PubMedGoogle Scholar
- 27.Kruschwitz M, Fritzsche G, Schwarting R, Micklem K, Mason DY, Falini B, Stein H. Ber-ACT8: A new monoclonal antibody defining a trimeric antigen associated with activated CD8 T cells, gut mucosa T cells, and hairy cell leukemia cells (submitted).Google Scholar
- 28.Schwarting R, Dienemann D, Kruschwitz M, Fritzsche G, Stein H. Specificities of monoclonal antibodies B-1y7 and HML-1 are identical. Blood 1990; 320.Google Scholar
- 29.Sperling M, Kaudewitz P, Braun-Falco O, Stein H. Reactivity of T cells in mycosis fungoides exhibiting marked epidermotropism with the monoclonal antibody HML-1 that defines a membrane molecule on human mucosal lymphocytes. 1989, Amer J Path 1989; 134: 955–960.Google Scholar
- 30.Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in human: Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990; 136: 1053–1068.PubMedGoogle Scholar